Agomab Acquires Origo Biopharma, Will Develop Fibrosis Therapies

Agomab Acquires Origo Biopharma, Will Develop Fibrosis Therapies

310627

Agomab Acquires Origo Biopharma, Will Develop Fibrosis Therapies

Agomab Therapeutics and Origo Biopharma are joining forces to develop new therapies for pulmonary fibrosis (PF) and other conditions caused by excessive tissue scarring, or fibrosis. “Agomab and Origo share a common vision that targeting growth factors has tremendous disease-modifying potential,” Tim Knotnerus, Agomab’s CEO, said in a press release. “This transaction delivers on Agomab’s growth strategy and brings together two teams that have complementary R&D [research and development] experience and establishes an exciting clinical…

You must be logged in to read/download the full post.